Indeed, the use of anti-PD-1 and anti-PD-L1 monoclonal antibodies (mAbs), in view of particularly encouraging results in patients with lung or melanoma, have been approved by the Food and Drug Administration (FDA) [17,18] (see paragraph 5.0). The gene discussed is CD274; the disease is melanoma.